Lornoxicam,clinical observation and peptide drugs in the treatment of osteoarthritis

VernacularTitle:氯诺昔康、骨肽等药物在治疗骨性关节炎中的临床观察
Author: Long GAO ; Ying CHEN ; Huan LIU ; Zhao YANG ; Huhu ZHANG
Keywords: osteoarthritis; peptide; lornoxicam; combination therapy; therapeutic effect
From: Chinese Journal of Biochemical Pharmaceutics 2017;37(9):308-309,311
CountryChina
Language:Chinese
Abstract: Objective To investigate the combined use of osteoarthritis treatment effect of lornoxicam and peptide drugs.Methods 260 patients with osteoarthritis treated in our hospital from May 2014 to June 2016 were selected, were randomly divided into study group and control group, each group of 130 cases.The patients in the control group were treated with sodium hyaluronate and lornoxicam, the study group was given bone peptide on the basis of the control group. The pain scores, knee function and adverse reactions were compared between the two groups.Results There was no significant difference in VAS and WOMAC scores between the two groups before treatment; after treatment, the improvement of VAS and WOMAC score in the study group was better than that in the control group (P<0.05). There was no significant difference in the incidence of adverse drug reactions between the two groups. Conclusion Sodium hyaluronate, bone peptide, lornoxicam and other drugs in the treatment of patients with osteoarthritis clinical efficacy is obvious, and fewer adverse reactions.